Key Takeaways
- NJ SOAR program aims to expand medication-assisted treatment access across primary care, emergency departments, and specialized clinics
- Buprenorphine prescribing waiver training enables primary care providers to offer office-based MAT
- Integrated MAT within primary care reduces barriers, stigma, and improves sustained engagement
- Methadone and naltrexone remain important MAT options alongside buprenorphine
- SOAR program success requires adequate funding, provider training, and patient education about MAT effectiveness
NJ SOAR Program Goals and Expansion Strategy
The New Jersey SOAR (Substance Use Disorder Opioid Addiction Recovery) program represents state initiative to dramatically expand medication-assisted treatment (MAT) access by integrating MAT into primary care, emergency departments, and community health settings rather than limiting it to specialized addiction treatment programs. This strategy recognizes that waiting for specialized treatment appointments causes delays, prevents treatment engagement, and contributes to overdose deaths. SOAR aims to make MAT available whenever and wherever patients access healthcare—primary care offices, hospitals, urgent care centers, community health centers. Early evidence suggests integration improves treatment engagement, retention, and outcomes.
SOAR includes provider training funding: offering buprenorphine prescribing waiver training to interested primary care physicians, nurse practitioners, and physician assistants; providing ongoing clinical support for newly-trained providers; coordinating with addiction specialists for complex cases; and integrating behavioral health referrals. The program's central insight is that MAT need not be exclusive to addiction specialists—appropriately trained primary care providers can safely prescribe buprenorphine, reducing waitlists and increasing access. This represents significant service expansion recognizing medication as front-line addiction treatment.
Integrating MAT into primary care reduces barriers and stigma while improving accessibility. SOAR represents evidence-based strategy scaling MAT statewide.
Buprenorphine Prescribing Expansion and Barriers
Buprenorphine represents gold-standard MAT for opioid addiction given its safety profile (ceiling effect on respiratory depression, lower abuse potential), flexibility (office-based prescribing), and effectiveness. Federal regulations require buprenorphine prescribers to obtain waiver authorization, complete training, and maintain specific patient-load limits. For years, these requirements restricted buprenorphine access; only small percentages of opioid-addicted individuals accessed buprenorphine MAT due to limited waived prescriber availability. SOAR removes barriers by funding training and credentialing for interested providers, rapidly expanding waived prescriber capacity.
New Jersey has invested in buprenorphine access expansion, removing prior authorization requirements and enabling rapid prescriber network growth. However, challenges persist: some primary care providers hesitate to prescribe buprenorphine citing addiction treatment concerns or capacity constraints; some insurance plans continue prior authorization despite state recommendations; patients sometimes distrust office-based settings for addiction treatment, preferring specialized programs. Continued advocacy emphasizing buprenorphine safety and effectiveness remains important. For New Jersey residents seeking immediate buprenorphine access, identifying waived prescribers (available through state health department lists) provides direct pathway.
Finding Buprenorphine Providers in New Jersey
Multiple resources help identify buprenorphine-waived prescribers statewide.
- New Jersey Department of Health prescriber directory: lists waived buprenorphine providers
- SAMHSA provider locator: national database searchable by location/insurance
- Local addiction treatment programs: can refer to or coordinate buprenorphine prescribing
- Insurance verification: ask your insurance provider for waived provider network
- Call 211 (United Way): information and referral service for addiction treatment
Emergency Department Integration and Overdose Survivor Engagement
SOAR includes emergency department engagement: overdose survivors presenting to ED receive treatment, Narcan education, and immediate buprenorphine initiation before ED discharge, rather than brief intervention and referral without engagement. This emergency department-based MAT initiation dramatically improves treatment engagement rates: individuals who begin buprenorphine immediately show vastly higher follow-up treatment engagement compared to those receiving only referrals. Emergency departments increasingly recognize opioid overdose as medical crisis warranting treatment initiation, not just resuscitation and discharge.
Emergency departments participating in SOAR programs coordinate with community providers for follow-up care: overdose survivors receiving ED-initiated buprenorphine receive warm handoff referrals to community providers for continued medication and behavioral health support. This continuity prevents treatment gaps that frequently precede relapse. From public health perspective, ED-initiated MAT saves lives by engaging individuals in acute crisis when motivation and opportunity align. Patients should know that if they present to NJ EDs following overdose, they can request buprenorphine initiation and referral for continued care.
ED buprenorphine initiation saved my life. They started treatment immediately, connected me with ongoing provider, and gave me path forward when I was desperate.
— NJ SOAR Program Participant
Methadone and Naltrexone as MAT Alternatives
While buprenorphine represents increasingly accessible primary MAT option through SOAR expansion, methadone and naltrexone remain important alternatives. Methadone maintenance, available through specialized opioid treatment programs (OTPs), offers highly effective treatment for severe opioid addiction, particularly for individuals with long histories of heroin use or who failed buprenorphine trials. Methadone requires daily clinic visits (initially observed directly) but is highly effective when engaged. Naltrexone (oral or long-acting injection Vivitrol) offers different mechanism—opioid antagonist preventing euphoria if opioids used—and works well for some individuals preferring opioid-free approach.
Choice among MAT options should reflect individual clinical factors: medication efficacy for individual's addiction severity, any previous MAT trials and responses, medical/psychiatric comorbidities, preference for medication type and prescribing setting, work/life logistics. Quality SOAR programs coordinate across medication options, enabling patient and provider collaboration selecting optimal approach. Some individuals cycle through MAT options: initially engaging buprenorphine, later transitioning to methadone if craving intensity increases, or trying naltrexone as relapse-prevention following detoxification. Flexibility and coordination across MAT options improves overall treatment outcomes.
Patient Education and MAT Stigma Reduction
Effective SOAR implementation requires patient and public education about MAT safety, effectiveness, and integration with behavioral health. Stigma persists: some individuals view buprenorphine as "substituting one addiction for another" rather than understanding it as medication with different neurobiological properties. Public campaigns emphasizing MAT research, patient testimonies, and clinician endorsements help reduce stigma. Patient education addressing concern ("Will I be dependent on buprenorphine?") acknowledges that yes, individuals become dependent on medication—but physical dependence differs fundamentally from addiction. Medication-supported recovery enables engagement in meaningful life activities; addiction prevents this. Understanding distinction is critical.
SOAR programs emphasize patient voice: recovery community members serving as peer specialists, patient testimonies demonstrating MAT effectiveness, and explicit acknowledgment of past stigmatizing treatment experiences. When individuals feel heard and respected, treatment engagement improves. Programs should create welcoming environments where individuals feel trusted as partners in recovery, not judged as failures. This cultural shift—from addiction treatment as punishment to addiction treatment as healthcare—depends on widespread stigma reduction and patient-centered care emphasis.
Trust SoCal Editorial Team, Clinical Review Board
Editorial & Clinical Review
